e15618 Background: Colorectal cancer (CRC) is the third most common cancer globally and ranks second as a cause of cancer-related death. As survival rates among CRC patients continue to rise, addressing accompanying metabolic comorbidities is becoming increasingly important. This study aims to explore the prevalence of metabolic comorbidities and metabolic syndrome among CRC patients, as well as their impact on survival. Methods: The ColoCare Study is a prospective cohort study conducted across seven U.S. and European sites. Data from a single site, Cedars-Sinai Medical Center in Los Angeles, California was analyzed. Adults with newly diagnosed stage I-IV CRC and available medical records were eligible. Basic demographic information and medical history, including hypertension, hyperlipidemia, and diabetes mellitus (DM) diagnosis at or before CRC diagnosis were collected by manually reviewing electronic medical records. Additionally, BMI was calculated using patients' weight and height at the time of diagnosis and classified according to the CDC’s published ranges. Patients were considered to have metabolic syndrome if they met three or more of the following criteria: hypertension, hyperlipidemia, DM, or obesity. Overall survival rates for patients with each metabolic condition were compared. Results: A total of 295 patients (58.3% male, 41.7% female, mean age at diagnosis = 58.3) were identified. 172 were non-Hispanic White (58.3%), 52 were Hispanic/Latino (17.6%), 36 (12.2%) were Asian, 27 (9.2%) were Black, and 8 (1.8%) were unknown/other. Metabolic conditions were prevalent in the cohort: hypertension affected 33.9%, hyperlipidemia affected 21.4%, and DM affected 13% of patients. Additionally, over half of the patients (56.6%) were overweight or obese. Individuals meeting criteria for metabolic syndrome (8.8%) had lower survival rates compared to those without this condition (73.1% vs. 81.4%). Similarly, patients with DM had lower survival rates compared to their counterparts without DM (72.5% vs. 82.0%). Patients with hypertension, hyperlipidemia, and elevated BMI did not have significantly different survival rates compared to patients without such conditions. Conclusions: Our study highlights the prevalence of metabolic comorbidities, specifically metabolic syndrome and DM, among CRC patients and emphasizes how these factors can impact patient outcomes post-diagnosis. This information is valuable for physicians when considering lifestyle changes or treatment strategies following CRC diagnosis. Further, it highlights the importance of coordination between oncologists and primary care providers to effectively manage metabolic diseases in CRC patients.

Metabolic disorders in patients diagnosed with colorectal cancer.